Skip to main content
. 2020 Apr 23;21(8):2983. doi: 10.3390/ijms21082983

Figure 3.

Figure 3

CA-IX pharmacological inhibitors increase the expression and activation of p-ERK1/2. MDA-MB-231 (A,B) and A549 (C,D) were treated with SLC-0111 and AA-06-05 [100–200 µM] for 30 min. The treatments were performed under experimental condition of medium with 1% FBS. Signals were evaluated through western blot and β-actin was used to normalize protein loading. For each experimental condition Arbitrary Densitometry Units (A.D.U.) ± SD were reported as pERK1/2/total ERK1/2 vs basal control. (n = 3). ** p < 0.01 and *** p < 0.001 vs. untreated cells (Ctr).